Clinical Late Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Clin Sci (Lond). 2024 Jun 5;138(11):687-697. doi: 10.1042/CS20240605.
Endothelin A and B receptors, together with sodium-glucose cotransporter-2 (SGLT-2) channels are important targets in improving endothelial function and intervention with inhibitors has been the subject of multiple mechanistic and clinical outcome trials over recent years. Notable successes include the treatment of pulmonary hypertension with endothelin receptor antagonists, and the treatment of heart failure and chronic kidney disease with SGLT-2 inhibitors. With distinct and complementary mechanisms, in this review, we explore the logic of combination therapy for a number of diseases which have endothelial dysfunction at their heart.
内皮素 A 和 B 受体以及钠-葡萄糖共转运蛋白-2 (SGLT-2) 通道是改善内皮功能的重要靶点，近年来，抑制剂的干预作用一直是多项机制和临床结局试验的主题。显著的成功包括内皮素受体拮抗剂治疗肺动脉高压，以及 SGLT-2 抑制剂治疗心力衰竭和慢性肾脏病。本文通过探索一些以内皮功能障碍为核心的疾病的联合治疗逻辑，研究了具有独特而互补机制的内皮素 A 和 B 受体以及钠-葡萄糖共转运蛋白-2 (SGLT-2) 通道。
